Works matching DE "CRIZOTINIB"

Results: 408

The Presence of ALK Alterations and Clinical Relevance of Crizotinib Treatment in Pediatric Solid Tumors.

Published in:

Pathology & Oncology Research, 2019, v. 25, n. 1, p. 217, doi. 10.1007/s12253-017-0332-1

By:

Felkai, Luca;
Bánusz, Rita;
Kovalszky, Ilona;
Sápi, Zoltán;
Garami, Miklós;
Papp, Gergő;
Karászi, Katalin;
Varga, Edit;
Csóka, Monika

Publication type:

Article

Complete and durable response to crizotinib in a patient with malignant pleural mesothelioma harboring CD74-ROS1 fusion.

Published in:

Journal of Cancer Research & Clinical Oncology, 2022, v. 148, n. 9, p. 2561, doi. 10.1007/s00432-022-04076-0

By:

Xie, Xuehua;
You, Mengxing;
Meng, Erhong;
Wang, Shunyou;
Niu, Beifang;
Huang, Weiming

Publication type:

Article

Crizotinib: aseptic abscesses in multiple organs during treatment of EML4-ALK-positive NSCLC.

Published in:

2021

By:

Weber, Daniel;
Decker, Miriam;
Schuster, Michael;
Folz, Sara;
Stürmer, Carsten Johannes;
Lutz, Manfred P.

Publication type:

Case Study

The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement.

Published in:

Journal of Cancer Research & Clinical Oncology, 2021, v. 147, n. 9, p. 2637, doi. 10.1007/s00432-021-03546-1

By:

Bilgin, Burak;
Şendur, Mehmet Ali Nahit;
Yücel, Şebnem;
Hizal, Mutlu;
Güner, Gürkan;
Akyürek, Nalan;
Erol, Cihan;
Akıncı, Muhammed Bülent;
Dede, Didem Şener;
Yalçın, Bülent;
Kılıçkap, Sadettin

Publication type:

Article

Impact of STAT1 polymorphisms on crizotinib-induced hepatotoxicity in ALK-positive non-small cell lung cancer patients.

Published in:

Journal of Cancer Research & Clinical Oncology, 2021, v. 147, n. 3, p. 725, doi. 10.1007/s00432-020-03476-4

By:

Xin, Shuang;
Fang, Wenfeng;
Li, Jianwen;
Li, Delan;
Wang, Changzheng;
Huang, Quanfei;
Huang, Min;
Zhuang, Wei;
Wang, Xueding;
Chen, Likun

Publication type:

Article

MET canonical transcript expression is a predictive biomarker for chemo-sensitivity to MET-inhibitors in hepatocellular carcinoma cell lines.

Published in:

Journal of Cancer Research & Clinical Oncology, 2021, v. 147, n. 1, p. 167, doi. 10.1007/s00432-020-03395-4

By:

Rashed, Wafaa M.;
Kandeil, Mohamed A.;
Mahmoud, Mohamed O.;
Maher, Doha;
Ezzat, Sameera;
Abdel-Rahman, Mohamed H.

Publication type:

Article

Reactive Oxygen Species (ROS)-Sensitive Prodrugs of the Tyrosine Kinase Inhibitor Crizotinib.

Published in:

Molecules, 2020, v. 25, n. 5, p. 1149, doi. 10.3390/molecules25051149

By:

Bielec, Bjoern;
Poetsch, Isabella;
Ahmed, Esra;
Heffeter, Petra;
Keppler, Bernhard K.;
Kowol, Christian R.

Publication type:

Article

Unexpected Rearrangement of N-Allyl-2-phenyl-4,5-Dihydrooxazole-4-Carboxamides to Construct Aza-Quaternary Carbon Centers.

Published in:

Molecules, 2019, v. 24, n. 24, p. 4495, doi. 10.3390/molecules24244495

By:

Choi, Goyeong;
Jo, Seoyoung;
Mun, Juyeon;
Jeong, Yonguk;
Kim, Seok-Ho;
Jung, Jong-Wha;
Garrido, Narciso M.

Publication type:

Article

Crizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Published in:

Oncology & Therapy, 2021, v. 9, n. 2, p. 505, doi. 10.1007/s40487-021-00155-3

By:

Cruz, Barbara D.;
Barbosa, Mariana M.;
Torres, Lucas L.;
Azevedo, Pamela S.;
Silva, Vânia E. A.;
Godman, Brian;
Alvares-Teodoro, Juliana

Publication type:

Article

Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib.

Published in:

2016

By:

Wong, Victor;
Pavlick, Dean;
Brennan, Tim;
Yelensky, Roman;
Crawford, John;
Ross, Jeffrey S.;
Miller, Vincent A.;
Malicki, Denise;
Stephens, Philip J.;
Ali, Siraj M.;
Hyunah Ahn;
Ahn, Hyunah

Publication type:

Case Study

Evaluation of the Effectiveness of Combined Treatment with the PD-L1 Inhibitor Atezolizumab and the c-MET Inhibitor Crizotinib in MCF-7 Breast Cancer Cells.

Published in:

Gazi Medical Journal, 2024, v. 35, p. 58

By:

Haklıgur, Neslihan;
Güler, Ahsen;
İnanç, Mevlüde

Publication type:

Article

Advances in MET tyrosine kinase inhibitors in gastric cancer.

Published in:

Cancer Biology & Medicine, 2024, v. 21, n. 6, p. 484, doi. 10.20892/j.issn.2095-3941.2024.0044

By:

Yifan Zhang;
Lin Shen;
Zhi Peng

Publication type:

Article

Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement: a case report.

Published in:

Cancer Biology & Medicine, 2018, v. 15, n. 2, p. 178, doi. 10.20892/j.issn.2095-3941.2018.0003

By:

Ling Zhang;
Yunxia Li;
Shaohong Zhang;
Chen Gao;
Keke Nie;
Youxin Ji

Publication type:

Article

Equivocal ALK fluorescence in-situ hybridization ( FISH) cases may benefit from ancillary ALK FISH probe testing.

Published in:

Histopathology, 2015, v. 67, n. 5, p. 654, doi. 10.1111/his.12708

By:

Selinger, Christina;
Cooper, Wendy;
Lum, Trina;
McNeil, Catriona;
Morey, Adrienne;
Waring, Paul;
Amanuel, Benhur;
Millward, Michael;
Peverall, Joanne;
Van Vliet, Chris;
Christie, Michael;
Tran, Yen;
Diakos, Connie;
Pavlakis, Nick;
Gill, Anthony J;
O'Toole, Sandra

Publication type:

Article

Case report: complete remission with crizotinib in ROS1 fusion-positive sinonasal mucosal melanoma.

Published in:

Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.942258

By:

Jun Cao;
Yaner Yu;
Yangkun Zhou;
Qing Ji;
Wenkang Qian;
Dongdong Jia;
Gu Jin;
Yajun Qi;
Xin Li;
Ningning Li;
Tao Li;
Meiyu Fang;
Hongchuan Jin

Publication type:

Article

Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy.

Published in:

Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.900966

By:

Woo Kyung Ryu;
Hyungkeun Cha;
Mi Hwa Park;
Jung Soo Kim;
Jeong-Seok Choi;
Lucia Kim;
Kyung-Hee Lee;
Hae-Seong Nam

Publication type:

Article

Case report: Prompt response to radiotherapy and chemotherapy combined with crizotinib in gingival sarcomatoid squamous cell carcinoma with MET 14 mutation.

Published in:

Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.1006516

By:

Zhenhua Sun;
Bingjie Xia;
Ming Zhang;
Shuai Xu;
Yingqian Ma;
Xianbo Zhang

Publication type:

Article

Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy.

Published in:

Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.976837

By:

Khan, Shaheer;
Lutzky, Jose;
Shoushtari, Alexander N.;
Jeter, Joanne;
Marr, Brian;
Olencki, Thomas E.;
Cebulla, Colleen M.;
Abdel-Rahman, Mohamed;
Harbour, J. William;
Sender, Naomi;
Nesson, Alexandra;
Singh-Kandah, Shahnaz;
Hernandez, Susana;
King, Jeanelle;
Katari, Manpreet S.;
Dimapanat, Lyssa;
Izard, Stephanie;
Ambrosini, Grazia;
Surriga, Oliver;
Rai, Alex J.

Publication type:

Article

Case Report: Durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon EGFR G719D/L861Q mutations and an acquired novel CUX1- MET fusion.

Published in:

Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.911362

By:

Lanzi Ou;
Yicong Tang;
Yanming Deng;
Lijie Guo;
Qingqing He;
Tingting He;
Weineng Feng

Publication type:

Article

Renal Abscess Caused by Crizotinib: A Rare Case Report.

Published in:

Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.920990

By:

Zhaojun Wan;
Kai Wang;
Xiangfu Yin;
Xiangting Guo;
Guoli Cheng;
Jihong Pan

Publication type:

Article

Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer.

Published in:

Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.921854

By:

Giunta, Emilio Francesco;
Signori, Alessio;
West, Howard Jack;
Metro, Giulio;
Friedlaender, Alex;
Parikh, Kaushal;
Banna, Giuseppe Luigi;
Addeo, Alfredo

Publication type:

Article

LMO7-ALK Fusion in a Lung Adenocarcinoma Patient With Crizotinib: A Case Report.

Published in:

Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.841493

By:

Yang, Yanlong;
Zheng, Hongbo;
Li, Zizhe;
Shi, Shuchen;
Zhong, Lang;
Gong, Longlong;
Lan, Bin

Publication type:

Article

A Combination of Cytokine-Induced Killer Cells With PD-1 Blockade and ALK Inhibitor Showed Substantial Intrinsic Variability Across Non-Small Cell Lung Cancer Cell Lines.

Published in:

Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.713476

By:

Li, Yutao;
Sharma, Amit;
Wu, Xiaolong;
Weiher, Hans;
Skowasch, Dirk;
Essler, Markus;
Schmidt-Wolf, Ingo G. H.

Publication type:

Article

Case Report: Short-Term Response to First-Line Crizotinib Monotherapy in a Metastatic Lung Adenocarcinoma Patient Harboring a Novel TPR-ROS1 Fusion.

Published in:

2022

By:

Wei, Shuli;
Hu, Mangsha;
Yang, Yan;
Huang, Xiaojie;
Li, Baizhou;
Ding, Liren;
Wang, Pingli

Publication type:

Case Study

Effective Systemic Treatment of Choroidal Metastases NSCLC With Surgery After Crizotinib: A Case Report.

Published in:

Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.789941

By:

Liu, Shilan;
Liu, Xiao;
Wang, Ting;
Zeng, Chunhua;
Ren, Baichen;
Yu, Xiaodan;
Xu, Min;
Li, Wenjuan;
Qiao, Zhihui;
You, Chuanyun;
Yang, Qinghui;
Chen, Mei

Publication type:

Article

A Risk Scoring System Utilizing Machine Learning Methods for Hepatotoxicity Prediction One Year After the Initiation of Tyrosine Kinase Inhibitors.

Published in:

Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.790343

By:

Han, Ji Min;
Yee, Jeong;
Cho, Soyeon;
Kim, Min Kyoung;
Moon, Jin Young;
Jung, Dasom;
Kim, Jung Sun;
Gwak, Hye Sun

Publication type:

Article

Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion.

Published in:

2022

By:

Chen, An-guo;
Chen, Dong-sheng;
Li, Si;
Zhao, Le-le;
Xiao, Ming-zhe

Publication type:

Case Study

Case Report: Dramatic Response to Crizotinib in a Patient With Non-Small Cell Lung Cancer Positive for a Novel ARL1-MET Fusion.

Published in:

Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.804330

By:

Ma, Qing;
Kong, Lingping;
Zhong, Diansheng

Publication type:

Article

An Insight on the Pathways Involved in Crizotinib and Sunitinib Induced Hepatotoxicity in HepG2 Cells and Animal Model.

Published in:

Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.749954

By:

Guo, Lin;
Tang, Tingli;
Fang, Dongmei;
Gong, Hui;
Zhang, Bikui;
Zhou, Yueyin;
Zhang, Leiyi;
Yan, Miao

Publication type:

Article

Mutation of MET D1228N as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with MET Y1003H Mutation.

Published in:

Lung Cancer: Targets & Therapy, 2024, v. 15, p. 123, doi. 10.2147/LCTT.S467584

By:

Zhu, Jinlian;
Chen, Jie;
Liu, Wei;
Zhang, Junling;
Gu, Yulan

Publication type:

Article

Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients.

Published in:

Lung Cancer: Targets & Therapy, 2020, v. 11, p. 19, doi. 10.2147/LCTT.S244366

By:

Mehta, Anurag;
Saifi, Mumtaz;
Batra, Ullas;
Suryavanshi, M;
Gupta, Kush

Publication type:

Article

Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date.

Published in:

Lung Cancer: Targets & Therapy, 2019, v. 10, p. 87, doi. 10.2147/LCTT.S190786

By:

Facchinetti, Francesco;
Friboulet, Luc

Publication type:

Article

Targeting RET-rearranged non-small-cell lung cancer: future prospects.

Published in:

Lung Cancer: Targets & Therapy, 2019, v. 10, p. 27, doi. 10.2147/LCTT.S192830

By:

Bronte, Giuseppe;
Ulivi, Paola;
Verlicchi, Alberto;
Cravero, Paola;
Delmonte, Angelo;
Crinò, Lucio

Publication type:

Article

Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification.

Published in:

Lung Cancer: Targets & Therapy, 2019, v. 10, p. 21, doi. 10.2147/LCTT.S190403

By:

Zhu, Viola W;
Schrock, Alexa B;
Ali, Siraj M;
Ou, Sai-Hong Ignatius

Publication type:

Article

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer.

Published in:

Lung Cancer: Targets & Therapy, 2019, v. 10, p. 11, doi. 10.2147/LCTT.S179349

By:

Barrows, Stephanie M;
Wright, Kelly;
Copley-Merriman, Catherine;
Kaye, James A;
Chioda, Marc;
Wiltshire, Robin;
Torgersen, Knut Martin;
Masters, Elizabeth T

Publication type:

Article

Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALKpositive non-small cell lung cancer who are resistant or intolerant to crizotinib.

Published in:

Lung Cancer: Targets & Therapy, 2017, v. 8, p. 169, doi. 10.2147/LCTT.S126507

By:

Jain, Rohit K.;
Hongbin Chen

Publication type:

Article

Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives.

Published in:

Lung Cancer: Targets & Therapy, 2016, v. 7, p. 83, doi. 10.2147/LCTT.S99303

By:

Leprieur, Etienne Giroux;
Fallet, Vincent;
Cadranel, Jacques;
Wislez, Marie

Publication type:

Article

Severe Erosive Pill Esophagitis Induced by Crizotinib Therapy: A Case Report and Literature Review.

Published in:

Case Reports in Gastrointestinal Medicine, 2016, p. 1, doi. 10.1155/2016/3562820

By:

Jung, Patrick;
Fortinsky, Kyle J.;
Gallinger, Zane R.;
Tartaro, Piero

Publication type:

Article

Stereoselective chemical N-glycoconjugation of amines via CO<sub>2</sub> incorporation.

Published in:

Nature Communications, 2024, v. 15, n. 1, p. 1, doi. 10.1038/s41467-024-54523-4

By:

Peng, Zihan;
Xiao, Qian;
Xia, Yan;
Xia, Mingyu;
Yu, Jia;
Fang, Pengfei;
Tang, Yu;
Yu, Biao

Publication type:

Article

Computational Investigation and Experimental Validation of Crizotinib Resistance Conferred by C1156Y Mutant Anaplastic Lymphoma Kinase.

Published in:

Molecular Informatics, 2015, v. 34, n. 2/3, p. 105, doi. 10.1002/minf.201400070

By:

Kumar, Anish;
Shanthi, V.;
Ramanathan, K.

Publication type:

Article

Retracted: Efficacy of Crizotinib Combined with Chemotherapy in Treating Advanced Non-Small-Cell Lung Cancer and Effect on Patients' Quality of Life and Adverse Reaction Rate.

Published in:

2022

By:

Engineering, Journal of Healthcare

Publication type:

Correction Notice

Efficacy of Crizotinib Combined with Chemotherapy in Treating Advanced Non-Small-Cell Lung Cancer and Effect on Patients' Quality of Life and Adverse Reaction Rate.

Published in:

Journal of Healthcare Engineering, 2022, p. 1, doi. 10.1155/2022/7898737

By:

Ma, Zaiqi;
Wang, Yun;
Sun, Yonghua;
Lin, Gaoyang;
Zhao, Zhenqing

Publication type:

Article

Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France.

Published in:

PLoS ONE, 2020, v. 15, n. 1, p. 1, doi. 10.1371/journal.pone.0226196

By:

Sivignon, Marine;
Monnier, Rémi;
Tehard, Bertrand;
Roze, Stéphane

Publication type:

Article

Synthesis of hapten, generation of specific polyclonal antibody and development of ELISA with high sensitivity for therapeutic monitoring of crizotinib.

Published in:

PLoS ONE, 2019, v. 14, n. 2, p. 1, doi. 10.1371/journal.pone.0212048

By:

Al-Shehri, Mona M.;
El-Azab, Adel S.;
El-Gendy, Manal A.;
Hamidaddin, Mohammed A.;
Darwish, Ibrahim A.

Publication type:

Article

Synthesis of (±)‐epi‐Jungianol by the Gold(I)‐Catalyzed Propargyl Claisen Rearrangement/Hydroarylation Cascade Reaction of Propargyl Vinyl Ethers.

Published in:

European Journal of Organic Chemistry, 2021, v. 2021, n. 8, p. 1266, doi. 10.1002/ejoc.202001555

By:

Rinaldi, Antonia;
Langé, Vittoria;
Scarpi, Dina;
Occhiato, Ernesto G.

Publication type:

Article

Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase‐Positive Non‐Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat.

Published in:

CTS: Clinical & Translational Science, 2021, v. 14, n. 2, p. 487, doi. 10.1111/cts.12921

By:

Hohmann, Nicolas;
Bozorgmehr, Farastuk;
Christopoulos, Petros;
Mikus, Gerd;
Blank, Antje;
Burhenne, Jürgen;
Thomas, Michael;
Haefeli, Walter E.

Publication type:

Article

Sufficiency of Single-Arm Studies to Support Registration of Targeted Agents in Molecularly Selected Patients with Cancer: Lessons from the Clinical Development of Crizotinib.

Published in:

CTS: Clinical & Translational Science, 2016, v. 9, n. 2, p. 63, doi. 10.1111/cts.12388

By:

Selaru, P;
Tang, Y;
Huang, B;
Polli, A;
Wilner, KD;
Donnelly, E;
Cohen, DP

Publication type:

Article

Central retinal artery occlusion, an early sign of crizotinib resistance in an alk positive adenocarcinoma of lung: A rare case report.

Published in:

2018

By:

Madabhavi, Irappa;
Patel, Apurva;
Anand, Asha;
Panchal, Harsha;
Parikh, Sonia

Publication type:

Case Study

Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas.

Published in:

British Journal of Haematology, 2015, v. 168, n. 6, p. 771, doi. 10.1111/bjh.13265

By:

Boi, Michela;
Zucca, Emanuele;
Inghirami, Giorgio;
Bertoni, Francesco

Publication type:

Article

Correction: Epithelial cell adhesion molecule (EpCAM) regulates HGFR signaling to promote colon cancer progression and metastasis.

Published in:

2024

By:

Lee, Chi-Chiu;
Yu, Chia-Jui;
Panda, Sushree Shankar;
Chen, Kai-Chi;
Liang, Kang-Hao;
Huang, Wan-Chen;
Wang, Yu-Shiuan;
Ho, Pei-Chin;
Wu, Han-Chung

Publication type:

Correction Notice